|
| Title | Institutions | First author | Journal | Publication year | IF (2019) | Total citations |
|
| Principles of bioactive lipid signalling: lessons from sphingolipids | Medical University of South Carolina, USA | Hannun, Yusuf A. | Nature Reviews Molecular Cell Biology | 2008 | 43.35 | 1884 |
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | University of Basel, Switzerland | Kappos, Ludwig | New England Journal of Medicine | 2010 | 70.67 | 1565 |
| Bioactive sphingolipids: metabolism and function | Medical University of South Carolina, USA | Bartke, Nana | Journal of Lipid Research | 2009 | 4.74 | 368 |
| Deregulation of sphingolipid metabolism in Alzheimer’s disease | Mount Sinai School of Medicine, USA | He, Xingxuan | Neurobiology of Aging | 2010 | 4.39 | 252 |
| Sphingolipids in mammalian cell signalling | University of Manchester, UK | Ohanian, J | Cellular and Molecular Life Sciences | 2001 | 7.01 | 183 |
| Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance | Medical University of South Carolina, USA | Ponnusamy, Suriyan | Future Oncology | 2010 | 2.27 | 182 |
| Sphingosine-1-phosphate produced by Sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis | Virginia Commonwealth University School of Medicine, USA | Nagahashi, Masayuki | Cancer Research | 2012 | 8.37 | 163 |
| How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries | Rambam Medical Center, Technion-Faculty of Medicine, Israel | Blumenfeld, Zeev | Oncologist | 2007 | 5.25 | 162 |
| Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial | Mount Sinai School of Medicine, USA, etc. | Lublin, Fred | Lancet | 2016 | 59.10 | 156 |
| Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study | University of Basel, Switzerland, etc. | Kappos, Ludwig | Lancet | 2018 | 59.10 | 150 |
|
